uniQure (NASDAQ:QURE) CEO Sells $26,079.34 in Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

uniQure Trading Up 2.3 %

QURE stock opened at $15.65 on Thursday. uniQure has a one year low of $3.73 and a one year high of $17.39. The stock has a market cap of $762.78 million, a price-to-earnings ratio of -3.16 and a beta of 0.89. The company has a fifty day moving average price of $6.64 and a two-hundred day moving average price of $6.22. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Equities analysts anticipate that uniQure will post -3.74 EPS for the current year.

Institutional Investors Weigh In On uniQure

Institutional investors have recently made changes to their positions in the company. abrdn plc lifted its holdings in uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of uniQure during the third quarter worth $7,360,000. Point72 Asset Management L.P. boosted its position in shares of uniQure by 336.1% in the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares during the period. FMR LLC grew its stake in shares of uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after acquiring an additional 346,274 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in uniQure during the second quarter worth about $815,000. Institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. The Goldman Sachs Group decreased their price target on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. Leerink Partners raised their target price on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday. Royal Bank of Canada upped their price target on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Tuesday. Finally, StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.57.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.